GERN

Geron Corporation

Fundamental data last updated:September 26, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

 


Analyze GERN on TradingView

VALUATION

P/E

-12.02

Market Cap ($M USD)

$801.90M

Forward P/E

1.95

PEG

0.00

PRICE TO SALES

4.09

PRICE TO BOOK

3.65

EV / EBITDA

-24.16

5-Year Average P/E

Free Cash Flow Yield

-15.75%

DCF Value

$-7.07

Graham Number

N/A

Price to FCF

-6.35

EV to FCF

-7.78

Earnings Yield

-8.32%

FCF Yield

-15.75%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.10

Next Year EPS Growth Estimate

$0.64

Next Year Revenue Growth Estimate

$918.71M

Return on Equity (ROE)

-28.90%

FREE CASH FLOW

Operating Margin

-19.05%

Debt-to-Equity

1.11

Piotroski F-Score

1

Altman Z-Score

-2.20

Return on Invested Capital (ROIC)

-8.11%

Current Ratio

6.78

Quick Ratio

6.78

Net Debt to EBITDA

-4.45

Interest Coverage

-1.18

Gross Profit margin

86.59%

FCF PER SHARE

$-0.19

REVENUE PER SHARE

$0.29

Analyze GERN on TradingView

Gainseekers Quantitative Analysis

Summary

Geron Corporation’s valuation paints a perplexing picture. Despite a Forward P/E of 2.16 suggesting potential growth, the market seems to have mispriced it relative to its DCF value, which is deeply negative. The Altman Z-score of -2.06 signals distress, raising red flags about financial stability. Meanwhile, an earnings yield in the red further underscores profitability challenges. The stock’s current pricing, well below its Graham Number, suggests a disconnect between market perception and intrinsic value.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Geron is poised to leverage advancements in AI and tech to enhance drug discovery and development. This industry is inherently aligned with cutting-edge research, offering potential resilience against technological shifts. However, execution remains key in translating these opportunities into tangible results.

The Bull Case

For the bullish investor, Geron's narrative is one of potential transformation. The Forward PEG ratio of 0.003 hints at undervaluation relative to growth prospects, while a robust current ratio of 6.78 indicates liquidity strength. Despite a low Piotroski F-Score, the company's gross profit margin of 86.59% suggests strong pricing power. These factors could appeal to those seeking a turnaround story with capital efficiency.

The Bear Case

However, the bear case is hard to ignore. The company's negative EPS and an EV to EBITDA of -26.29 highlight severe profitability issues. With a Price/Book ratio of 4.05, the stock appears overvalued given its financial distress. Additionally, a negative FCF yield and Altman Z-score indicate structural weaknesses that could deter risk-averse investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$5.89

Institutional Ownership %

1-Year Beta

0.68

Insider Buying % (6 Mo)

Distance to 52-Week High

60.80%

Distance to 52-Week Low

16.80%

EARNINGS SURPRISE %

66.67%

50-DAY SMA

$1.51

200-DAY SMA

$1.41

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.